PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1629297
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1629297
Thyroid Ablation Devices Market size was valued at USD 169.87 Million in 2023, expanding at a CAGR of 9.45% from 2024 to 2032.
Thyroid ablation devices are medical instruments used to treat thyroid-related disorders, such as thyroid cancers and benign thyroid nodules, by minimally invasive procedures. These utilize advanced energy-based technologies for destroying abnormal thyroid tissue, primarily through radiofrequency, microwave, and laser ablation. The main goal of thyroid ablation is reducing the size of thyroid nodules, killing cancerous cells, and eliminating symptoms associated with thyroid gland diseases without surgical intervention. During a thyroid ablation procedure, the device directly applies energy to the targeted tissue, which results in heat that kills the undesirable cells. These treatments are guided by imaging technologies such as ultrasound, CT scans, or MRI to ensure accuracy & minimum damage to surrounding healthy tissues. Thyroid ablation has become a popular alternative as it is minimally invasive, thus leading to less recovery time, less scarring, and fewer chances of complications compared to traditional surgery.
Thyroid Ablation Devices Market- Market Dynamics
Rising prevalence rates of thyroid cancer and benign thyroid conditions primarily boost the market for thyroid ablation devices. According to the American Cancer Society, an estimated 52,000 new cases of thyroid cancer were diagnosed in the US in 2023, with cases increasing globally. The aging population is a crucial factor, especially in developed regions. It is contributing to higher incidents of thyroid disorders and creating a greater need for efficient, less invasive treatments. The global trend for minimal invasiveness surgery supported by better imaging technologies such as ultrasound and CT scans is another strong driver. These technologies also enhance the precision & efficiency of ablation procedures. Moreover, improvement in healthcare infrastructure and growing awareness of thyroid disorders in emerging markets, especially in the Asia-Pacific region, will be expected to fuel the demand for thyroid ablation devices.
The market for thyroid ablation devices has immense growth potential, driven by the adoption of microwave and laser ablation technologies that provide improved treatment capabilities for larger tumors. Devices that can treat both malignant and benign conditions will create a larger market opportunity. Moreover, the trend of increasing outpatient procedures, especially in ambulatory surgical centers, is significant for expansion in this market. The next-generation image-guided devices that can better target and cause less tissue damage are expected to boost market growth further. Further, increasing investments in healthcare innovation & government funding for cancer-related research will also create long-term opportunities for market players. However, the high cost of advanced ablation devices limits their accessibility, especially in low-income regions. Furthermore, the complexity of some procedures & the requirement for skilled professionals to perform these treatments may limit the market expansion in certain regions.
Thyroid Ablation Devices Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 9.45% over the forecast period (2024-2032)
Based on product segmentation, Radiofrequency Ablation (RFA) was predicted to show maximum market share in the year 2023
Based on application segmentation, Thyroid cancer was the leading application in 2023
Based on region, North America was the leading revenue generator in 2023
The Global Thyroid Ablation Devices Market is segmented based on Type, Application, End Use, and Region.
By product, the market is divided into image-guided ablation, radiofrequency ablation (RFA), microwave ablation (MWA), and others. The radiofrequency ablation (RFA) segment occupies the largest share of the global thyroid ablation devices market. This is due to RFA's long track record of safety and efficacy and being well-established in the clinic. RFA is quite preferred for treating thyroid cancers and benign nodules of the thyroid gland, as it destroys targeted tissue with minimal risk and recovery time. Additionally, the growing trend toward minimally invasive procedures and the expanding access to RFA technologies in developed and emerging markets supports its leading role as the preferred treatment modality in thyroid ablation. The microwave ablation (MWA) segment is growing at the fastest rate during the forecast period. This rapid growth is attributed to MWA's ability to treat larger tumors, have more effective outcomes in cases, and offer faster ablation times, where conventional techniques might struggle. MWA has the potential to be more effective in the precise destruction of tissues without causing any damage to the surrounding tissues, thus raising its applications in benign and malignant conditions of the thyroid. The growing demand for non-surgical treatments and advancements in microwave technology are boosting the adoption of MWA.
Based on application, the market is segmented into thyroid cancer and thyroid nodules. The thyroid cancer segment acquired the largest market share. Thyroid cancer is one of the fastest-growing cancers, especially among the young, and hence, the need for non-surgical treatments like ablation is on the rise. According to the American Cancer Society, 52,000 annual new cases were reported in the US alone in 2023. The thyroid ablation devices are also efficient and minimally invasive, thus saving more time during recovery than traditional surgery. This makes them a widely used device for treating thyroid cancer worldwide. The thyroid nodules segment is projected to grow at a healthy rate in the market. Innovations in imaging technologies, such as ultrasound have significantly boosted the increase in the detection rate of thyroid nodules. Moreover, the rise in the adoption of less invasive procedures over surgery for benign conditions also drives thyroid ablation devices. However, thyroid nodules are common among older adults. Patients are seeking less invasive alternatives to manage their thyroid condition. The National Institute of Health (NIH) believes that, at any time, approximately 50% of adults may possess thyroid nodules, a major driver in the direction of this market to expand within this segment.
Thyroid Ablation Devices Market- Geographical Insights
Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.
North America leads as the largest market in the thyroid ablation devices market. This is largely contributed by the incidence rate of thyroid cancer and thyroid disorders and the availability of better healthcare infrastructure. The region is more developed with a well-defined healthcare system and thus supports medical device technologies. The US is the leader in this region, driven by high healthcare expenditure and aging populations. Asia-Pacific is projected to grow at a rapid pace during the forecast period. Factors fueling this growth are a rapid rise in thyroid diseases in China and India and improving healthcare access. Furthermore, the adoption of advanced medical technologies and the shift toward minimally invasive procedures are key drivers. Growth in the Asia-Pacific market is also supported by expanding government healthcare initiatives and the rising availability of specialized cancer treatment centers.
The market for thyroid ablation devices is highly competitive. Key market participants are developing innovative and minimal-invasive devices in various forms, such as RFA, LA, and MWA. Other players in the market are also smaller and niche firms whose products focus on specific unmet needs for patients or regions. Factors that govern this market's competition dynamics include product innovation, regulatory approval, pricing, and collaborations with healthcare delivery providers. Technologies such as better imaging integration and live monitoring have been some other factors that improve the interest in thyroid ablation devices, enabling them to perform better and safer procedures. Furthermore, the players are looking into combination therapies and broadening their product portfolio to treat malignant and benign thyroid conditions. Propelling demand for minimally invasive procedures and the propelling prevalence of thyroid-related disorders globally also fuel the competition among companies to innovate and differentiate themselves in a rapidly changing healthcare environment.
February 2024: Medtronic plc announced a collaboration with Google Cloud to leverage AI & cloud computing for improved patient outcomes and healthcare delivery. This partnership can potentially enhance the development and application of ablation technologies, including those used in thyroid treatment.
March 2024: Integra LifeSciences announced the expansion of its manufacturing facility in Plainsboro, New Jersey. This expansion will increase production capacity for various medical devices, including those used in minimally invasive procedures such as ablation therapies.
April 2024: Theraclion announced positive results from its clinical trial evaluating the efficacy & safety of its Echopulse system for treating benign thyroid nodules. The results demonstrated promising outcomes for patients, highlighting the potential of this technology in thyroid ablation.
May 2024: Johnson & Johnson announced an investment of $1 billion in its R&D efforts focused on developing innovative medical devices & technologies. This significant investment will likely support advancements in ablation technologies, including those used in thyroid treatment.
June 2024: BVM Medical Systems announced the successful completion of a clinical trial evaluating the safety & efficacy of its new ablation device for treating liver tumors. While focused on liver cancer, this success demonstrates the company's expertise in developing innovative ablation technologies that could be applied to other areas, including thyroid treatment.